Loading...
•
Sep 30
Mesa Labs Q2 2026 Earnings Report
Mesa Labs reported solid second quarter results with revenue growth and improved operating income.
Key Takeaways
Mesa Laboratories, Inc. announced strong second fiscal quarter results, with total revenues increasing by 5.0% to $60.7 million and operating income surging by 34.7% to $4.7 million. Non-GAAP adjusted operating income excluding unusual items also saw a healthy increase of 6.1% and represented 25.1% of revenues, indicating robust profitability despite macroeconomic uncertainties and specific segment challenges.
Total revenues increased by 5.0% to $60,737,000 compared to the same period last year.
Operating income significantly increased by 34.7% to $4,724,000.
Non-GAAP adjusted operating income excluding unusual items grew by 6.1% and was 25.1% as a percentage of revenues.
The company achieved 3.7% core organic revenue growth, driven by strong performance in Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics outside of China, offsetting softness in Sterilization and Disinfection Control and headwinds in Clinical Genomics China.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Mesa Labs Revenue by Geographic Location
Revenue by Segment
Sterilization and Disinfection Control Revenue
CapyFin.comBiopharmaceutical Development Revenue
CapyFin.comCalibration Solutions Revenue
CapyFin.comClinical Genomics Revenue
CapyFin.comRevenue by Geographic Location
China Revenue
CapyFin.comOutside of China Revenue
CapyFin.com Forward Guidance
Mesa Labs anticipates sequential revenue increases in the third fiscal quarter of 2026 and expects continued decreases in Clinical Genomics China revenues for the remainder of the fiscal year. The company plans to reinvest cost savings into the SDC division to fuel long-term growth.
Positive Outlook
- Expects revenues to sequentially increase in 3Q26.
- Plans to reinvest approximately $0.9 million of cost savings into SDC to fuel long-term growth.
- Cost reductions are expected to generate $2.3 million of net annualized cost savings.
- Anticipates significant decrease in outside professional services expenses for SDC during the second half of FY26.
- Cost reductions in Clinical Genomics will further expand the Division’s contribution margins in the future while not impacting growth outside of China.
Challenges Ahead
- Expects continued decreases in China revenues for the rest of the fiscal year compared to the same period in the prior year.
- Macroeconomic uncertainty persists.
- Ongoing regulatory headwinds in the CG China diagnostics market.
- Impact of tariffs and foreign currency translation on gross profit percentages.
- Softness in SDC deliveries noted in the current quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income